Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Trial Profile

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs ZW 25 (Primary)
  • Indications Cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Zymeworks
  • Most Recent Events

    • 05 Dec 2017 According to a Zymeworks media release, the dose escalation portion of the study enrolled 22 patients, Enrollment is underway for the second part of the study utilizing ZW25 every other week at 20 mg/kg in four expansion cohorts. The company plans to provide an update on the expansion cohort portion of the trial at the American Society of Clinical Oncology Annual Meeting in 2018.
    • 05 Dec 2017 According to a Zymeworks media release, results from the dose escalation portion of the study have been presented at the San Antonio Breast Cancer Symposium.
    • 05 Dec 2017 Results from the dose escalation portion of the study published in Zymeworks media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top